Functional Genomics Market Report 2026

The functional genomics market size has grown rapidly in recent years. It will grow from $14.84 billion in 2025 to $16.96 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to expansion of genomics research funding, increasing availability of sequencing technologies, growth in academic genomics research, rising demand for functional gene analysis, improvements in bioinformatics tools.

The functional genomics market size is expected to see rapid growth in the next few years. It will grow to $28.71 billion in 2030 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, rising investments in genomic data analytics, expansion of gene editing research applications, growing collaboration between academia and industry, increasing focus on translational genomics research. Major trends in the forecast period include increasing adoption of high-throughput functional genomics tools, rising integration of multi-omics analysis platforms, growing use of ai in gene function interpretation, expansion of automated genomic workflows, enhanced focus on disease mechanism discovery.

The rising investment in research and development is expected to drive the growth of the functional genomics market in the forecast period. Research and development refers to structured activities aimed at creating, improving, and innovating products, technologies, or knowledge through systematic investigation. Investment in research and development is increasing as organizations prioritize innovation to maintain competitiveness, leading to greater allocation of resources toward new product development, technological advancement, and emerging market opportunities. Increased research and development spending benefits functional genomics by advancing gene identification and functional analysis, enhancing understanding of complex biological systems, and supporting the development of precise therapeutic approaches. For instance, in February 2024, according to Biospace, a US-based online pharmaceutical platform, global biopharma research and development funding reached $72 billion in 2023, rising from $61 billion in 2022. Therefore, growing investment in research and development is fueling the expansion of the functional genomics market.

Leading companies operating in the functional genomics market are prioritizing the development of advanced methodologies, such as high-throughput sequencing, to deliver highly accurate and comprehensive insights into complex genomes. High-throughput sequencing is a technique that enables the rapid and simultaneous sequencing of large volumes of DNA or RNA, allowing large-scale analysis of genetic information. For example, in February 2025, Roche, a Switzerland-based pharmaceutical company, introduced sequencing by expansion (SBX) technology, establishing a new category within next-generation sequencing. SBX chemistry, combined with an advanced sensor module, supports ultra-fast, scalable, and high-throughput sequencing across a broad range of applications. This innovative approach converts DNA or RNA sequences into a detectable surrogate polymer known as an Xpandomer through a precise biochemical process. Xpandomers, which are fifty times longer than the original nucleic acid, translate sequence information into strong, low-noise signals for reliable detection. By utilizing CMOS-based sensors with parallel processing, this method delivers highly accurate single-molecule nanopore sequencing with exceptional speed and versatility.

In January 2025, Vividion Therapeutics Inc., a US-based biopharmaceutical company focused on discovering and developing small-molecule therapeutics, acquired Tavros Therapeutics Inc. for an undisclosed amount. Through this acquisition, Vividion intends to expand its functional genomics capabilities and strengthen drug discovery efforts, particularly in oncology and immunology, by integrating Tavros’s genomic screening platform with Vividion’s chemoproteomics expertise to enable identification of novel drug targets. Tavros Therapeutics Inc. is a US-based biotechnology company specializing in genomic screening technologies for target discovery.

Major companies operating in the functional genomics market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Perkin Elmer Inc., Revvity Inc., Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN NV, Integrated DNA Technologies Inc., Promega Corporation, Pacific Biosciences of California Inc., Genomics Ltd., MEDiC LLC, Enhanc3D Genomics Ltd., Samplix, Arima Genomics Inc., Phase Genomics Inc.

North America was the largest region in the functional genomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the functional genomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the functional genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the functional genomics market by increasing costs of imported sequencing instruments, reagents, laboratory automation systems, and data processing hardware. Research institutions and biopharmaceutical companies in North America and Europe are most affected due to dependence on imported high-end genomic equipment, while Asia-Pacific faces cost pressures on instrument manufacturing and exports. These tariffs are raising research project costs and extending procurement cycles. However, they are also encouraging local manufacturing of laboratory instruments, regional reagent production, and domestic bioinformatics solution development.

The functional genomics market research report is one of a series of new reports that provides functional genomics market statistics, including functional genomics industry global market size, regional shares, competitors with a functional genomics market share, detailed functional genomics market segments, market trends and opportunities, and any further data you may need to thrive in the functional genomics industry. This functional genomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Functional genomics is the scientific study of how genes and other genomic components function and interact within an organism. It aims to identify the roles genes play in regulating biological processes and how they influence physical traits and behaviors. By analyzing patterns of gene expression and the impact of genetic alterations, functional genomics uncovers the mechanisms that control cells, tissues, and entire organisms.

The primary products of functional genomics include kits and assays and instruments. Kits and assays are standardized laboratory tools developed to detect, quantify, or analyze specific biomolecules, genes, or proteins. It utilizes various technologies such as next-generation sequencing (NGS), microarray analysis, CRISPR and gene editing technologies, and RNA sequencing (RNA-seq) and is used by multiple end-users, including academic and research institutes, pharmaceutical and biopharmaceutical companies, contract research organizations (CROs), clinical laboratories, and agricultural biotechnology companies.

The functional genomics market consists of revenues earned by entities by providing services such as gene expression profiling, epigenomic profiling, phenotypic screening, and variant effect analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The functional genomics market also includes sales of microarray scanners, thermal cyclers, fluorometers, and bioanalyzers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.